CTNM (Contineum Therapeutics) Marketable Securities : $182.82 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Contineum Therapeutics's Marketable Securities for the quarter that ended in Dec. 2024 was $182.82 Mil.

Contineum Therapeutics's annual Marketable Securities increased from Dec. 2022 ($41.67 Mil) to Dec. 2023 ($109.66 Mil) and increased from Dec. 2023 ($109.66 Mil) to Dec. 2024 ($182.82 Mil).

Contineum Therapeutics Marketable Securities Historical Data

The historical data trend for Contineum Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Marketable Securities Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Marketable Securities

64.37

41.67

109.66

182.82

Contineum Therapeutics Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Marketable Securities	Get a 7-Day Free Trial					109.66	101.64	141.42	173.02	182.82

Contineum Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Contineum Therapeutics (NAS:CTNM) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Contineum Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

3565 General Atomics Court, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.